尼莫地平治疗蛛网膜下腔出血脑血管痉挛的有效性和安全性分析

doi:10.3969/j.issn.1006-6233.2018.03.014

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (1316 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨尼莫地平治疗蛛网膜下腔出血脑血管痉挛的有效性和安全性。方法: 收集2015年1月至2017年1月入院的108例蛛网膜下腔出血脑血管痉挛患者随机分为两组,对照组患者给予常规治疗,尼莫地平组患者则加用尼莫地平,比较两组患者GCS评分、Hunt-Hess分级、GOS评分、BI指数、疾病相关参数与不良反应。结果: 尼莫地平组患者治疗后GCS评分组间比较显著性高于对照组,Hunt-Hess分显著性低于对照组;治疗后3个月GOS评分组间比较显著性低于对照组,BI指数显著性高于对照组;治疗后左侧TCD、右侧TCD、血肿量、IL-6、SBP与DBP水平组间比较均显著性低于对照组,差异有统计学意义(P<0.05);两组患者治疗期间药物不良反应发生率与总发生率比较差异无统计学意义(P>0.05)。结论: 尼莫地平治疗蛛网膜下腔出血脑血管痉挛的疗效显著,安全性较高,具有借鉴意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：尼莫地平, 蛛网膜下腔出血, 脑血管痉挛

Abstract：Objective: To investigate the efficacy and safety of nimodipine in the treatment of cerebral vasospasm caused by subarachnoid hemorrhage. Methods: 108 patients with SAH admitted to our hospital from January 2015 to January 2017 were randomly divided into two groups. Patients in the control group were given routine treatment, nimodipine plus nimodipine, The GCS score, Hunt-Hess grade, GOS score, BI index, disease-related parameters and adverse reactions were compared between the two groups. Results: The scores of GCS in the nimodipine group were significantly higher than those in the control group after treatment, and the scores of Hunt-Hess in the nimodipine group were lower than those in the control group. The GOS scores in the 3-month group were significantly lower than those in the control group (P <0.05). After treatment, the left TCD, the right TCD, the amount of hematoma, the levels of IL-6, SBP and DBP in the two groups were significantly lower than those in the control group There was no significant difference between the two groups in the incidence of adverse drug reactions and the overall incidence of treatment (P> 0.05). Conclusion: Nimodipine is effective in treating cerebral vasospasm of subarachnoid hemorrhage and has high safety.

Key words： Nimodipine Subarachnoid hemorrhage Cerebral vasospasm Adverse reactions

基金资助:广东省茂名市科技计划项目,(编号:20130330)

引用本文:

刘小军, 吴开毅, 刘南午, 邱观养, 邓耀芳. 尼莫地平治疗蛛网膜下腔出血脑血管痉挛的有效性和安全性分析[J]. 河北医学, 2018, 24(3): 405-408.
LIU Xiaojun, WU Kaiyi, LIU Nanwu, et al. Efficacy and Safety of Nimodipine in Treatment of Cerebral Vasospasm Caused by Subarachnoid Hemorrhage. HeBei Med, 2018, 24(3): 405-408.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.03.014 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I3/405

[1] 周桂龙,侍海存,赵强,等.法舒地尔联用尼莫地平预防动脉瘤性蛛网膜下腔出血后迟发性脑血管痉挛的疗效观察[J].中国实用神经疾病杂志,2012,15(13):9~12.
[2] 斯良楠,孙晓川,张晓冬.经动脉灌注尼莫地平治疗蛛网膜下腔出血后脑血管痉挛[J].中国介入影像与治疗学,2015,12(9):527~531.
[3] 叶宇,贾军,石小峰,等.经动脉局部灌注尼莫地平防治动脉瘤性蛛网膜下腔出血后脑血管痉挛临床研究[J].中国实用神经疾病杂志,2012,15(8):11~14.
[4] 杨彬源,陈桂增,王本艳,等.马来酸桂哌齐特联合尼莫地平治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛疗效观察[J].海南医学,2017,28(6):971~973.
[5] 郭志彬.尼莫地平防治创伤性蛛网膜下腔出血早期脑血管痉挛[J].中国实用神经疾病杂志,2012,15(5):80~81.
[6] Anand S, Goel G, Gupta V. Continuous intra-arterial dilatation with nimodipine and milrinone for refractory cerebral vasospasm[J].Neurosurg Anesthesiol,2014,26(1):92~93.
[7] Bege N, Renette T, Endres T, et al. In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm[J]. Eur Pharm Biopharm,2013,84(1):99~105.
[8] 李婉秋,程晓玲,程伟,等.尼莫地平联合法舒地尔防治蛛网膜下腔出血术后脑血管痉挛及脑保护效果观察[J].中国实用神经疾病杂志,2015,18(22):97~98.
[9] 徐东勋,伍雪英,杨友松.尼莫地平联合帕伐他汀预防蛛网膜下腔出血后脑血管痉挛的效果观察及对内皮素-1、一氧化氮的影响[J].实用医院临床杂志,2016,13(3):48~50.
[10] 冯新华,苏金花,赵菊芳.尼莫地平治疗蛛网膜下腔出血后继发脑血管痉挛的临床研究[J].中国处方药,2016,14(4):58~59.
[11] 周晓忠,叶兰凤,杨少春,等.尼莫地平不同给药途径防治蛛网膜下腔出血脑血管痉挛的疗效观察[J].药品评价,2016,13(16):38~40.
[12] 陈向林,胡扬真,毛振敏.尼莫地平灌注联合脑脊液置换术治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的疗效分析[J].湖南中医药大学学报,2013,33(6):33~34.